Judith Shizuru

4.9/5

Biography

I am a member of the Stanford Blood and Marrow Transplantation (BMT) faculty, the Stanford Immunology Program and the Institute of Stem Cell Biology and Regenerative Medicine. I have attended on the BMT clinical service since 1997, and I oversee a research laboratory. My current clinical efforts and basic research focus on improving the safety and efficacy of hematopoietic cell transplantation (HCT) which is the most widely practiced and powerful form of cellular therapy. To achieve this goal we address two fundamental issues of HCT – the preparation of the recipient to accept a transplanted hematopoietic graft, and the impact of the graft cellular content on the success of the therapy. We have applied our expertise to develop novel ways to achieve engraftment of blood forming stem cells with the goal to replace chemotherapy and radiation. We have also developed the tools and methods that will allow us to transplant grafts of pure blood forming stem cells with the goal to eliminate potentially harmful passenger cells contained in a blood stem cell graft.

View Full Biography

Professional Summary

Education & Certifications

Board Certification: American Board of Internal Medicine, Internal Medicine (2022)
Residency: UCSF Department of Medicine (1994) CA
Fellowship: Stanford University Medical Center (1997) CA
- Medical Education: Stanford University School of Medicine (1992) CA

View More Education & Certifications

Honors & Awards

Career Award in the Biomedical Sciences, Burroughs Wellcome Fund (1996-2000)
Excellence in Research in the Field of Hematopoiesis, Cheryl Whitlock Award (1996)
Junior Faculty Scholars Award, Howard Hughes Medical Institute (1996-2000)
- Postdoctoral Fellowship, Juvenile Diabetes Foundation (1986-1988)
- Postdoctoral Fellowship, Juvenile Diabetes Foundation (1989-1991)
- Postdoctoral Fellowship, Juvenile Diabetes Foundation (1991-1993)
- Scholar Award, Amy Strelzer Manasevit (2001)

View More Honors & Awards

Memberships

Member, Scientific Advisory Board, Shoreline Biosciences (2021 - Present)
Director, rBIO (2020 - Present)
Chair, Scientific Advisory Board, Jasper Therapeutics, Inc (2019 - Present)
- Director, Jasper Therapeutics, Inc (2018 - Present)

View More Memberships

Administrative Appointments

Member, Stanford Diabetes Research Center (2018 - Present)

Publications

Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation.
Dickson, T. M., Kusnierz-Glaz, C. R., Blume, K. G., Negrin, R. S., Hu, W. W., Shizuru, J. A., … Stockerl-Goldstein, K. E. (1999). Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biology of Blood and Marrow Transplantation , 5(5), 299–305.
Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.
Ito, M., & Shizuru, J. A. (1999). Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model. Biology of Blood and Marrow Transplantation , 5(6), 357–368.
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy
Hu, W. W., Negrin, R. S., Stockerl-Goldstein, K., JOHNSTON, L. J., Shizuru, J. A., Wong, R. M., … Blume, K. G. (2000). Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(1), 58–69.
- Effect of oral glutamine supplementation during bone marrow transplantation
  Dickson, T. M. C., Wong, R. M., Negrin, R. S., Shizuru, J. A., JOHNSTON, L. J., Hu, W. W., … Stockerl-Goldstein, K. E. (2000). Effect of oral glutamine supplementation during bone marrow transplantation. JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 24(2), 61–66.
- Transplantation of highly purified CD34(+)Thy-I+ hematopoietic stem cells in patients with metastatic breast cancer
  Negrin, R. S., Atkinson, K., Leemhuis, T., Hanania, E., Juttner, C., Tierney, K., … Klein, J. (2000). Transplantation of highly purified CD34(+)Thy-I+ hematopoietic stem cells in patients with metastatic breast cancer. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(3), 262–71.
- Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation
  Cao, T. M., Negrin, R. S., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., Taylor, T. L., … Hu, W. W. (2000). Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(4), 387–94.
- Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection
  Shizuru, J. A., Weissman, I. L., Kernoff, R., Masek, M., & Scheffold, Y. C. (2000). Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 97(17), 9555–9560.
- Lymphoid development from stem cells and the common lymphocyte progenitors
  Akashi, K., Kondo, M., Cheshier, S., Shizuru, J., Gandy, K., Domen, J., … Weissman, I. L. (1999). Lymphoid development from stem cells and the common lymphocyte progenitors. Presented at the 64th Symposia: Signaling and Gene Expression in the Immune System, NEW YORK,NY: COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT.
- Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production
  Baker, J., Verneris, M. R., Ito, M., Shizuru, J. A., & Negrin, R. S. (2001). Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. BLOOD, 97(10), 2923–31.
- High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience
  Cao, T. M., Horning, S. F., Negrin, R. S., Hu, W. W., Johnston, L. F., Taylor, T. L., … Stockerl-Goldstein, K. (2001). High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(5), 294–301.
- Immunity to infections following hematopoietic cell transplantation
  Brown, J. M., Weissman, I. L., & Shizuru, J. A. (2001). Immunity to infections following hematopoietic cell transplantation. CURRENT OPINION IN IMMUNOLOGY, 13(4), 451–457.
- Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8(+) NK-T cells in the treatment of lymphoma
  Verneris, M. R., Ito, M., Baker, E., Arshi, A., Negrin, R. S., & Shizuru, J. A. (2001). Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8(+) NK-T cells in the treatment of lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(10), 532–42.
- Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease
  Stuart, M. J., Chao, N. S., Horning, S. J., Wong, R. M., Negrin, R. S., JOHNSTON, L. J., … Goldstein, S. (2001). Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(10), 552–60.
- Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients
  Auffermann-Gretzinger, S., Lossos, I. S., Vayntrub, T. A., Leong, W., GRUMET, F. C., Blume, K. G., … Shizuru, J. A. (2002). Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. BLOOD, 99(4), 1442–48.
- Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation
  Millan, T. L. T., Shizuru, J. A., Hoffmann, P., Dejbakhsh-Jones, S., Scandling, J. D., GRUMET, F. C., … Strober, S. (2002). Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. TRANSPLANTATION, 73(9), 1386–91.
- Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion
  Higuchi, M., Zeng, D. F., Shizuru, J., Gworek, J., Dejbakhsh-Jones, S., Taniguchi, M., & Strober, S. (2002). Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion. JOURNAL OF IMMUNOLOGY, 169(10), 5564–70.
- Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice
  Beilhack, G. F., Scheffold, Y. C., Weissman, I. L., TAYLOR, C., Jerabek, L., Burge, M. J., … Shizuru, J. A. (2003). Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. DIABETES, 52(1), 59–68.
- Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation
  Shilling, H. G., McQueen, K. L., Cheng, N. W., Shizuru, J. A., Negrin, R. S., & Parham, P. (2003). Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. BLOOD, 101(9), 3730–40.
- Biology of hematopoietic stem cells and progenitors: Implications for clinical application
  Kondo, M., Wagers, A. J., Manz, M. G., Prohaska, S. S., Scherer, D. C., Beilhack, G. E., … Weissman, I. L. (2003). Biology of hematopoietic stem cells and progenitors: Implications for clinical application. ANNUAL REVIEW OF IMMUNOLOGY, 21, 759–806.
- Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation
  Arber, C., Bitmansour, A., Sparer, T. E., Higgins, J. P., Mocarski, E. S., Weissman, I. L., … Brown, J. M. Y. (2003). Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation. BLOOD, 102(2), 421–28.
- Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
  Horwitz, S. M., Negrin, R. S., Blume, K. G., Breslin, S., Stuart, M. J., Stockerl-Goldstein, K. E., … Horning, S. J. (2004). Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. BLOOD, 103(3), 777–83.
- ANTI-CD4 MONOCLONAL-ANTIBODIES IN THERAPY - CREATION OF NONCLASSICAL TOLERANCE IN THE ADULT
  Shizuru, J. A., Alters, S. E., & Fathman, C. G. (1992). ANTI-CD4 MONOCLONAL-ANTIBODIES IN THERAPY - CREATION OF NONCLASSICAL TOLERANCE IN THE ADULT. IMMUNOLOGICAL REVIEWS, 129, 105–30.
- Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice
  Cao, T. M., Lo, B., Ranheim, E. A., GRUMET, F. C., & Shizuru, J. A. (2003). Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 100(20), 11571–76.
- Approaches to transplantation tolerance in humans
  Strober, S., Lowsky, R. J., Shizuru, J. A., Scandling, J. D., & Millan, M. T. (2004). Approaches to transplantation tolerance in humans. TRANSPLANTATION, 77(6), 932–36.
- Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose
  Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., … Lowsky, R. (2005). Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose. BLOOD, 105(6), 2300–2306.
- Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells
  Scheffold, C., Scheffold, J. C., Cao, T. M., Gworek, J., & Shizuru, J. A. (2005). Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(1), 1–12.
- Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
  Johnston, L. J., Brown, J., Shizuru, J. A., Stockerl-Goldstein, K. E., Stuart, M. J., Blume, K. G., … Chao, N. J. (2005). Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(1), 47–55.
- Hematopoietic stem and progenitor cells: Clinical and preclinical regeneration of the hematolymphoid system
  Shizuru, J. A., Negrin, R. S., & Weissman, I. L. (2005). Hematopoietic stem and progenitor cells: Clinical and preclinical regeneration of the hematolymphoid system. ANNUAL REVIEW OF MEDICINE, 56, 509–38.
- CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies
  Cao, T. M., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., … Lowsky, R. (2005). CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. EXPERIMENTAL HEMATOLOGY, 33(3), 279–85.
- Prevention of type 1 diabetes with major histocompatibility complex-compatible and nonmarrow ablative hematopoietic stem cell transplants
  Beilhack, G. F., Landa, R. R., Masek, M. A., & Shizuru, J. A. (2005). Prevention of type 1 diabetes with major histocompatibility complex-compatible and nonmarrow ablative hematopoietic stem cell transplants. DIABETES, 54(6), 1770–79.
- Protective conditioning for acute graft-versus-host disease
  Lowsky, R., Takahashi, T., Liu, Y. P., Dejbakhsh-Jones, S., GRUMET, F. C., Shizuru, J. A., … Strober, S. (2005). Protective conditioning for acute graft-versus-host disease. NEW ENGLAND JOURNAL OF MEDICINE, 353(13), 1321–31.
- Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
  Hegenbart, U., Niederwieser, D., Sandmaier, B. M., Maris, M. B., Shizuru, J. A., Greinix, H., … STORB, R. (2006). Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. JOURNAL OF CLINICAL ONCOLOGY, 24(3), 444–453.
- High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
  Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., … Stockerl-Goldstein, K. E. (2006). High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(7), 703–11.
- Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes
  Chaparro, R. J., Konigshofer, Y., Beilhack, G. F., Shizuru, J. A., McDevitt, H. O., & Chien, Y.-H. (2006). Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 103(33), 12475–80.
- Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation
  Baron, F., Storb, R., Storer, B. E., Maris, M. B., Niederwieser, D., Shizuru, J. A., … Sandmaier, B. M. (2006). Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. JOURNAL OF CLINICAL ONCOLOGY, 24(25), 4150–4157.
- Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma
  Rezvani, A. R., Storer, B., Maris, M., Sorror, M. L., Agura, E., Maziarz, R. T., … Maloney, D. G. (2008). Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 26(2), 211–17.
- Tolerance and chimerism after renal and hematopoietic-cell transplantation.
  Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Millan, M. T., Shizuru, J. A., … Strober, S. (2008). Tolerance and chimerism after renal and hematopoietic-cell transplantation. New England Journal of Medicine, 358(4), 362–68.
- Hepatic parenchymal replacement in mice by transplanted allogeneic hepatocytes is facilitated by bone marrow transplantation and mediated by CD4 cells
  Streetz, K. L., Doyonnas, R., Grimm, D., Jenkins, D. D., Fuess, S., Perryman, S., … Kay, M. A. (2008). Hepatic parenchymal replacement in mice by transplanted allogeneic hepatocytes is facilitated by bone marrow transplantation and mediated by CD4 cells. HEPATOLOGY, 47(2), 706–18.
- GENETIC-ANALYSIS OF DIABETES IN THE NONOBESE DIABETIC MOUSE .1. MHC AND T-CELL RECEPTOR BETA-GENE EXPRESSION
  Livingstone, A., Edwards, C. T., Shizuru, J. A., & Fathman, C. G. (1991). GENETIC-ANALYSIS OF DIABETES IN THE NONOBESE DIABETIC MOUSE .1. MHC AND T-CELL RECEPTOR BETA-GENE EXPRESSION. JOURNAL OF IMMUNOLOGY, 146(2), 529–34.
- GENETIC DISSECTION OF T-CELL RECEPTOR-V-BETA GENE REQUIREMENTS FOR SPONTANEOUS MURINE DIABETES
  Shizuru, J. A., TAYLOREDWARDS, C., Livingstone, A., & Fathman, C. G. (1991). GENETIC DISSECTION OF T-CELL RECEPTOR-V-BETA GENE REQUIREMENTS FOR SPONTANEOUS MURINE DIABETES. JOURNAL OF EXPERIMENTAL MEDICINE, 174(3), 633–38.
- ANTI-CD8 ABROGATES EFFECT OF ANTI-CD4-MEDIATED ISLET ALLOGRAFT SURVIVAL IN RAT MODEL
  SEYDEL, K., Shizuru, J., Grossman, D., Wu, A., Alters, S., & Fathman, C. G. (1991). ANTI-CD8 ABROGATES EFFECT OF ANTI-CD4-MEDIATED ISLET ALLOGRAFT SURVIVAL IN RAT MODEL. DIABETES, 40(11), 1430–34.
- TRANSGENIC MICE FOR THE STUDY OF DIABETES-MELLITUS
  Shizuru, J. A., & Sarvetnick, N. (1991). TRANSGENIC MICE FOR THE STUDY OF DIABETES-MELLITUS. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2(3), 97–104.
- Complementing mutations in core binding factor leukemias: from mouse models to clinical applications
  Mueller, A., Duque, J., Shizuru, J. A., & Luebbert, M. (2008). Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. ONCOGENE, 27(44), 5759–5773.
- Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning
  Sorror, M. L., Storer, B. E., Sandmaier, B. M., Maris, M., Shizuru, J., Maziarz, R., … Maloney, D. G. (2008). Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. JOURNAL OF CLINICAL ONCOLOGY, 26(30), 4912–4920.
- The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases
  Weissman, I. L., & Shizuru, J. A. (2008). The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. BLOOD, 112(9), 3543–3553.
- Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow
  Tsao, G. J., Allen, J. A., Logronio, K. A., Lazzeroni, L. C., & Shizuru, J. A. (2009). Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(9), 3288–93.
- TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
  Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., … Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099–1109.
- Identification of a Major Susceptibility Locus for Lethal Graft-versus-Host Disease in MHC-Matched Mice
  Cao, T. M., Lazzeroni, L. C., Tsai, S., Pang, W. W., Kao, A., Camp, N. J., … Shizuru, J. A. (2009). Identification of a Major Susceptibility Locus for Lethal Graft-versus-Host Disease in MHC-Matched Mice. JOURNAL OF IMMUNOLOGY, 183(1), 462–69.
- Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure
  Benjamin, J. E., Chen, G. L., Cao, T. M., Cao, P. D., Wong, R. M., Sheehan, K., … Laport, G. G. (2010). Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. BONE MARROW TRANSPLANTATION, 45(2), 303–9.
- INDUCTION OF DONOR-SPECIFIC UNRESPONSIVENESS TO CARDIAC ALLOGRAFTS IN RATS BY PRETRANSPLANT ANTI-CD4 MONOCLONAL-ANTIBODY THERAPY
  Shizuru, J. A., Seydel, K. B., Flavin, T. F., Wu, A. P., Kong, C. C., Hoyt, E. G., … Fathman, C. G. (1990). INDUCTION OF DONOR-SPECIFIC UNRESPONSIVENESS TO CARDIAC ALLOGRAFTS IN RATS BY PRETRANSPLANT ANTI-CD4 MONOCLONAL-ANTIBODY THERAPY. TRANSPLANTATION, 50(3), 366–73.
- Ineffective Vaccination against Solid Tumors Can Be Enhanced by Hematopoietic Cell Transplantation
  Filatenkov, A., Mueller, A. M. S., Tseng, W. W.-L., Dejbakhsh-Jones, S., Winer, D., Luong, R., … Strober, S. (2009). Ineffective Vaccination against Solid Tumors Can Be Enhanced by Hematopoietic Cell Transplantation. JOURNAL OF IMMUNOLOGY, 183(11), 7196–7203.
- The biology of allogeneic hematopoietic cell resistance.
  Shizuru, J. A., Bhattacharya, D., & Cavazzana-Calvo, M. (2010). The biology of allogeneic hematopoietic cell resistance. Biology of Blood and Marrow Transplantation , 16(1), S2–7.
- Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
  Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., … Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145–54.
- Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia
  Gyurkocza, B., Storb, R., Storer, B. E., Chauncey, T. R., Lange, T., Shizuru, J. A., … Sandmaier, B. M. (2010). Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 28(17), 2859–2867.
- Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
  Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., Lowsky, R., … Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192–99.
- Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation.
  Müller, A. M. S., Linderman, J. A., Florek, M., Miklos, D., & Shizuru, J. A. (2010). Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proceedings of the National Academy of Sciences of the United States of America, 107(33), 14721–26.
- Rapid Reconstitution of Antibody Responses Following Transplantation of Purified Allogeneic Hematopoietic Stem Cells
  Linderman, J. A., & Shizuru, J. A. (2011). Rapid Reconstitution of Antibody Responses Following Transplantation of Purified Allogeneic Hematopoietic Stem Cells. JOURNAL OF IMMUNOLOGY, 186(7), 4191–99.
- Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
  Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., Brown, J., … Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581–88.
- Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma
  Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., Lowsky, R., … Stockerl-Goldstein, K. (2012). Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. BONE MARROW TRANSPLANTATION, 47(4), 516–21.
- Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
  Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., … Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679–87.
- Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells
  Mueller, A. M. S., Kohrt, H. E. K., Cha, S., Laport, G., Klein, J., Guardino, A. E., … Shizuru, J. A. (2012). Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(1), 125–33.
- A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies
  Chen, G. L., Arai, S., Flowers, M. E. D., Otani, J. M., Qiu, J., Cheng, E. C., … Miklos, D. B. (2011). A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. BLOOD, 118(15), 4070–78.
- Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants
  Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Sarwal, M., Millan, M. T., … Strober, S. (2012). Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants. AMERICAN JOURNAL OF TRANSPLANTATION, 12(5), 1133–45.
- Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity
  Mueller, A. M. S., Shashidhar, S., Kuepper, N. J., Kohrt, H. E. K., Florek, M., Negrin, R. S., … Shizuru, J. A. (2012). Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109(15), 5820–25.
- Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
  Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., … Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145–54.
- The road to purified hematopoietic stem cell transplants is paved with antibodies.
  Logan, A. C., Weissman, I. L., & Shizuru, J. A. (2012). The road to purified hematopoietic stem cell transplants is paved with antibodies. Current Opinion in Immunology, 24(5), 640–48.
- Host-derived CD4+T cells attenuate stem cellmediated transfer of autoimmune arthritis in lethally irradiated C57BL/6.g7 mice
  Rajasekaran, N., Wang, N., Phi Truong, P., Rinderknecht, C., Macaubas, C., Beilhack, G. F., … Mellins, E. D. (2013). Host-derived CD4+T cells attenuate stem cellmediated transfer of autoimmune arthritis in lethally irradiated C57BL/6.g7 mice. ARTHRITIS AND RHEUMATISM, 65(3), 681–92.
- CARDIAC ALLOGRAFT PROLONGATION IN MICE TREATED WITH COMBINED POSTTRANSPLANTATION TOTAL-LYMPHOID IRRADIATION AND ANTI-L3T4 ANTIBODY THERAPY
  TRAGER, D. K., Banks, B. A., Rosenbaum, G. E., HOLM, B. I., Shizuru, J. A., Strober, S., & Fathman, C. G. (1989). CARDIAC ALLOGRAFT PROLONGATION IN MICE TREATED WITH COMBINED POSTTRANSPLANTATION TOTAL-LYMPHOID IRRADIATION AND ANTI-L3T4 ANTIBODY THERAPY. TRANSPLANTATION, 47(4), 587–91.
- IMMUNOTHERAPY OF THE NONOBESE DIABETIC MOUSE - TREATMENT WITH AN ANTIBODY TO T-HELPER LYMPHOCYTES
  Shizuru, J. A., TAYLOREDWARDS, C., Banks, B. A., Gregory, A. K., & Fathman, C. G. (1988). IMMUNOTHERAPY OF THE NONOBESE DIABETIC MOUSE - TREATMENT WITH AN ANTIBODY TO T-HELPER LYMPHOCYTES. SCIENCE, 240(4852), 659–62.
- USE OF ANTI-L3T4 AND ANTI-IA TREATMENTS FOR PROLONGATION OF XENOGENEIC ISLET TRANSPLANTS
  Kaufman, D. S., Kong, C. S., Shizuru, J. A., Gregory, A. K., & Fathman, C. G. (1988). USE OF ANTI-L3T4 AND ANTI-IA TREATMENTS FOR PROLONGATION OF XENOGENEIC ISLET TRANSPLANTS. TRANSPLANTATION, 46(2), 210–15.
- VASCULAR ADDRESSINS ARE INDUCED ON ISLET VESSELS DURING INSULITIS IN NONOBESE DIABETIC MICE AND ARE INVOLVED IN LYMPHOID-CELL BINDING TO ISLET ENDOTHELIUM
  Hanninen, A., TAYLOR, C., STREETER, P. R., Stark, L. S., SARTE, J. M., Shizuru, J. A., … Michie, S. A. (1993). VASCULAR ADDRESSINS ARE INDUCED ON ISLET VESSELS DURING INSULITIS IN NONOBESE DIABETIC MICE AND ARE INVOLVED IN LYMPHOID-CELL BINDING TO ISLET ENDOTHELIUM. JOURNAL OF CLINICAL INVESTIGATION, 92(5), 2509–2515.
- Anti-CD4 antibodies in diabetes.
  Shizuru, J. A., & Fathman, C. G. (1993). Anti-CD4 antibodies in diabetes. Immunology Series, 59, 237–52.
- THE USE OF GRANZYME A AS A MARKER OF HEART-TRANSPLANT REJECTION IN CYCLOSPORINE OR ANTI-CD4 MONOCLONAL ANTIBODY-TREATED RATS
  CHEN, R. H., IVENS, K. W., Alpert, S., Billingham, M. E., Fathman, C. G., Flavin, T. F., … Griffiths, G. M. (1993). THE USE OF GRANZYME A AS A MARKER OF HEART-TRANSPLANT REJECTION IN CYCLOSPORINE OR ANTI-CD4 MONOCLONAL ANTIBODY-TREATED RATS. TRANSPLANTATION, 55(1), 146–53.
- Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment.
  Shizuru, J. A., Jerabek, L., Edwards, C. T., & Weissman, I. L. (1996). Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment. Biology of Blood and Marrow Transplantation , 2(1), 3–14.
- From stem cells to lymphocytes: Biology and transplantation
  Aguila, H. L., Akashi, K., Domen, J., Gandy, K. L., Lagasse, E., Mebius, R. E., … Weissman, I. L. (1997). From stem cells to lymphocytes: Biology and transplantation. IMMUNOLOGICAL REVIEWS, 157, 13–40.
- Kinetics of mixed chimerism in peripheral blood hematopoietic subpopulations from 120 patients after nonmyeloablative hematopoietic stem cell transplant.
  Little, M. T., Baker, J. E., Sandmaier, B. M., Maris, M. B., Maloney, D., Gooley, T., … STORB, R. (2002). Kinetics of mixed chimerism in peripheral blood hematopoietic subpopulations from 120 patients after nonmyeloablative hematopoietic stem cell transplant. BLOOD, 100(11), 39A–39A.
- ISLET ALLOGRAFT SURVIVAL AFTER A SINGLE COURSE OF TREATMENT OF RECIPIENT WITH ANTIBODY TO L3T4
  Shizuru, J. A., Gregory, A. K., CHAO, C. T. B., & Fathman, C. G. (1987). ISLET ALLOGRAFT SURVIVAL AFTER A SINGLE COURSE OF TREATMENT OF RECIPIENT WITH ANTIBODY TO L3T4. SCIENCE, 237(4812), 278–280.
- A chromosome 16 quantitative trait locus regulates allogeneic bone marrow engraftment in nonmyeloablated mice
  Cao, T. M., Thomas, A., Wang, Y., Tsai, S., Logronio, K., & Shizuru, J. A. (2009). A chromosome 16 quantitative trait locus regulates allogeneic bone marrow engraftment in nonmyeloablated mice. BLOOD, 114(1), 202–10.
- THE MOLECULAR-BASIS OF ANTIGEN-SPECIFIC RECOGNITION BY LYMPHOCYTES-T
  Danska, J. S., Livingstone, A. M., Shizuru, J., & Fathman, C. G. (1990). THE MOLECULAR-BASIS OF ANTIGEN-SPECIFIC RECOGNITION BY LYMPHOCYTES-T. Presented at the COLLOQUIUM ON DEFENSE MOLECULES, LAKE TAHOE,CA: WILEY-LISS, INC.
- Of mice and men
  Shizuru, J. A. (2006). Of mice and men. BLOOD, 107(7), 2589–2590.
- A non-myeloablative conditioning regimen followed by progenitor cell (CD34+) infusion after kidney transplantation can achieve mixed chimerism and immunosuppressive drug withdrawal
  Millan, M. T., Shizuru, J. A., Hoffmann, P., Dejbakhsh-Jones, S., Scandling, J. D., GRUMET, F. C., … Strober, S. (2002). A non-myeloablative conditioning regimen followed by progenitor cell (CD34+) infusion after kidney transplantation can achieve mixed chimerism and immunosuppressive drug withdrawal. FASEB JOURNAL, 16(5), A1030–A1030.
- Toward regenerative medicine
  Lagasse, E., Shizuru, J. A., Uchida, N., Tsukamoto, A., & Weissman, I. L. (2001). Toward regenerative medicine. IMMUNITY, 14(4), 425–436.
- Immune reconstitution
  Weissman, I. L., & Shizuru, J. A. (1999). Immune reconstitution. NEW ENGLAND JOURNAL OF MEDICINE, 341(16), 1227–1229.
- Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
  Rotta, M., Storer, B. E., Sahebi, F., Shizuru, J. A., Bruno, B., Lange, T., … Maloney, D. G. (2009). Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. BLOOD, 113(14), 3383–3391.
- Non-myeloablative hematopoietic stem cell transplantation
  Maris, M., Sandmaier, B. M., Maloney, D. G., McSweeney, P. A., Woolfrey, A., Chauncey, T., … Storb, R. (2001). Non-myeloablative hematopoietic stem cell transplantation. TRANSFUSION CLINIQUE ET BIOLOGIQUE, 8(3), 231–234.
- Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas
  Shustov, A. R., Gooley, T. A., Sandmaier, B. M., Shizuru, J., Sorror, M. L., Sahebi, F., … Maloney, D. G. (2010). Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. BRITISH JOURNAL OF HAEMATOLOGY, 150(2), 170–178.
- Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts
  Gyurkocza, B., Cao, T. M., Storb, R. F., Lange, T., Leisenring, W., Franke, G. N., … Sandmaier, B. M. (2009). Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15(10), 1314–22.
- Allogeneic hematopoietic stem cell transplantation: From the nuclear age into the twenty-first century
  Storb, R., McSweeney, P. A., Sandmaier, B. M., Nash, R. A., Georges, G., Maloney, D. G., … Niederwieser, D. (2000). Allogeneic hematopoietic stem cell transplantation: From the nuclear age into the twenty-first century. TRANSPLANTATION PROCEEDINGS, 32(7), 2548–2549.
- Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML
  Kerbauy, F. R., STORB, R., Hegenbart, U., Gooley, T., Shizuru, J., Al-Ali, H. K., … Sandmaier, B. M. (2005). Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. LEUKEMIA, 19(6), 990–997.
- Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience
  Rezvani, A. R., Norasetthada, L., Gooley, T., Sorror, M., Bouvier, M. E., Sahebi, F., … Maloney, D. G. (2008). Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. BRITISH JOURNAL OF HAEMATOLOGY, 143(3), 395–403.
- STRUCTURE, FUNCTION, AND IMMUNE PROPERTIES OF REASSOCIATED ISLET CELLS
  Shizuru, J., Trager, D., & Merrell, R. C. (1985). STRUCTURE, FUNCTION, AND IMMUNE PROPERTIES OF REASSOCIATED ISLET CELLS. DIABETES, 34(9), 898–903.
- INHIBITION OF RAT MIXED LYMPHOCYTE PANCREATIC-ISLET CULTURES WITH ANTI-IA IMMUNOTOXIN
  Shizuru, J. A., Ramakrishnan, S., Hunt, T., Merrell, R. C., & Fathman, C. G. (1986). INHIBITION OF RAT MIXED LYMPHOCYTE PANCREATIC-ISLET CULTURES WITH ANTI-IA IMMUNOTOXIN. TRANSPLANTATION, 42(6), 660–666.
- GENETIC-CONTROL OF DIABETES-MELLITUS
  Weatherall, D., Sarvetnick, N., & Shizuru, J. A. (1992). GENETIC-CONTROL OF DIABETES-MELLITUS. Presented at the 3RD WORLD CONF ON DIABETES RESEARCH, MONTE CARLO,MONACO: SPRINGER VERLAG.
- Nonmyeloablative hematopoietic stem cell transplantation: Transplantation for the 21(st) century
  Maris, M., Woolfrey, A., McSweeney, P. A., Sandmaier, B. M., Nash, R. A., Georges, G., … STORB, R. (2001). Nonmyeloablative hematopoietic stem cell transplantation: Transplantation for the 21(st) century. FRONTIERS IN BIOSCIENCE-LANDMARK, 6, G13–G16.
- Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation
  Mielcarek, M., Burroughs, L., Leisenring, W., Diaconescu, R., Martin, P. J., Sandmaier, B. M., … STORB, R. (2005). Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. BRITISH JOURNAL OF HAEMATOLOGY, 129(3), 381–391.
- B6.g7 mice reconstituted with BDC2·5 non-obese diabetic (BDC2·5NOD) stem cells do not develop autoimmune diabetes.
  Rajasekaran, N., Wang, N., Hang, Y., Macaubas, C., Rinderknecht, C., Beilhack, G. F., … Mellins, E. D. (2013). B6.g7 mice reconstituted with BDC2·5 non-obese diabetic (BDC2·5NOD) stem cells do not develop autoimmune diabetes. Clinical and Experimental Immunology, 174(1), 27–37.
- Pathways analysis of differential gene expression induced by engrafting doses of total body irradiation for allogeneic bone marrow transplantation in mice
  Chen, X., Wang, Y., Li, Q., Tsai, S., Thomas, A., Shizuru, J. A., & Cao, T. M. (2013). Pathways analysis of differential gene expression induced by engrafting doses of total body irradiation for allogeneic bone marrow transplantation in mice. IMMUNOGENETICS, 65(8), 597–607.
- Fine mapping of the Bmgr5 quantitative trait locus for allogeneic bone marrow engraftment in mice
  Wang, Y., Chen, X., Tsai, S., Thomas, A., Shizuru, J. A., & Cao, T. M. (2013). Fine mapping of the Bmgr5 quantitative trait locus for allogeneic bone marrow engraftment in mice. IMMUNOGENETICS, 65(8), 585–596.
- Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
  McSweeney, P. A., Niederwieser, D., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., … Storb, R. F. (2001). Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. BLOOD, 97(11), 3390–3400.
- Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report
  Schultz, K. R., Miklos, D. B., Fowler, D., Cooke, K., Shizuru, J., Zorn, E., … Pavletic, S. Z. (2006). Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(2), 126–37.
- LOSS OF PANCREATIC-ISLET TOLERANCE INDUCED BY BETA-CELL EXPRESSION OF INTERFERON-GAMMA
  Sarvetnick, N., Shizuru, J., Liggitt, D., Martin, L., McIntyre, B., Gregory, A., … Stewart, T. (1990). LOSS OF PANCREATIC-ISLET TOLERANCE INDUCED BY BETA-CELL EXPRESSION OF INTERFERON-GAMMA. NATURE, 346(6287), 844–847.
- INFLAMMATORY DESTRUCTION OF PANCREATIC BETA-CELLS IN GAMMA-INTERFERON TRANSGENIC MICE
  Sarvetnick, N., Shizuru, J., Liggitt, D., & Stewart, T. (1989). INFLAMMATORY DESTRUCTION OF PANCREATIC BETA-CELLS IN GAMMA-INTERFERON TRANSGENIC MICE. COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 54, 837–842.
- Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.
  Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., … Lowsky, R. (2014). Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biology of Blood and Marrow Transplantation , 20(6), 837–43.
- Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment.
  Müller, A. M. S., Poyser, J., Küpper, N. J., Burnett, C., Ko, R. M., Kohrt, H. E. K., … Shizuru, J. A. (2014). Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment. Blood, 123(18), 2882–92.
- Nonmyeloablative hematopoietic cell transplantation - Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect
  Fenstein, L., SANDMAIER, B., Maloney, D., McSweeney, P. A., Maris, M., Flowers, C., … STORB, R. (2001). Nonmyeloablative hematopoietic cell transplantation - Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Presented at the 3rd International Conference on Hematopoietic Stem Cells: Genetics and Medicine, TUBINGEN,GERMANY: NEW YORK ACAD SCIENCES.
- Non-myeloablative haematopoietic stem cell transplants
  STORB, R., McSweeney, P. A., Sandmaier, B. M., Nash, R. A., Georges, G., Maloney, D., … Niederwieser, D. (2000). Non-myeloablative haematopoietic stem cell transplants. Presented at the 4th International Stem Cell Workshop on High-Dose Therapy and Transplantation of Haematopoietic Stem Cells, BAD SAAROW PIESKOW,GERMANY: BLACKWELL WISSENSCHAFTS-VERLAGGMBH.
- Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion.
  Filatenkov, A., Baker, J., Müller, A. M., Ahn, G.-O., Kohrt, H., Dutt, S., … Strober, S. (2014). Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion. Radiation Research, 182(2), 163–69.
- Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: The effect of postgrafting mycophenolate mofetil dosing
  Maris, M. B., Sandmaier, B. M., Storer, B. E., Maloney, D. G., Shizuru, J. A., Agura, E., … Storb, R. (2006). Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: The effect of postgrafting mycophenolate mofetil dosing. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(4), 454–465.
- Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma
  Georges, G. E., Maris, M. B., Maloney, D. G., Sandmaier, B. M., Sorror, M. L., Shizuru, J. A., … Storb, R. (2007). Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 13(4), 423–432.
- HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia
  Baron, F., Maris, M. B., Storer, B. E., Sandmaier, B. M., Stuart, M. J., McSweeney, P. A., … Storb, R. (2005). HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(4), 272–279.
- Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases
  Georges, G. E., Maris, M., Sandmaier, B. M., Maloney, D. G., Feinstein, L., Niederweiser, D., … STORB, R. (2002). Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. Presented at the 29th World Congress of the International-Society-of-Hematology, SEOUL,SOUTH KOREA: SPRINGER JAPAN KK.
- Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MNF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases
  Niederwieser, D., Maris, M., Shizuru, J. A., Petersdorf, E., Hegenbart, U., Sandmaier, B. M., … Storb, R. F. (2003). Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MNF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. BLOOD, 101(4), 1620–1629.
- Non-myeloablative transplantation.
  Maloney, D. G., Sandmaier, B. M., Mackinnon, S., & Shizuru, J. A. (2002). Non-myeloablative transplantation. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 392–421.
- SELECTIVE T-CELL DEPLETION WITH OX-38 ANTI-CD4 MONOCLONAL-ANTIBODY PREVENTS CARDIAC ALLOGRAFT-REJECTION IN RATS
  Flavin, T., Shizuru, J., SEYDEL, K., Wu, A., Fujimoto, N., Hoyt, E. G., … Starnes, V. A. (1990). SELECTIVE T-CELL DEPLETION WITH OX-38 ANTI-CD4 MONOCLONAL-ANTIBODY PREVENTS CARDIAC ALLOGRAFT-REJECTION IN RATS. JOURNAL OF HEART TRANSPLANTATION, 9(5), 482–488.
- European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
  Medeiros, B. C., Tian, L., Robenson, S., Laport, G. G., JOHNSTON, L. J., Shizuru, J. A., … Lowsky, R. (2014). European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. BLOOD CANCER JOURNAL, 4.
- Chimerism, Graft Survival, and Withdrawal of Immunosuppressive Drugs in HLA Matched and Mismatched Patients After Living Donor Kidney and Hematopoietic Cell Transplantation.
  Scandling, J. D., Busque, S., Shizuru, J. A., Lowsky, R., Hoppe, R., Dejbakhsh-Jones, S., … Strober, S. (2015). Chimerism, Graft Survival, and Withdrawal of Immunosuppressive Drugs in HLA Matched and Mismatched Patients After Living Donor Kidney and Hematopoietic Cell Transplantation. American Journal of Transplantation , 15(3), 695–704.
- Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.
  Percival, M.-E. M., Medeiros, B. C., Tian, L., Robeson, S., Laport, G. G., Johnston, L. J., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Bone Marrow Transplantation.
- Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.
  Filatenkov, A., Baker, J., Mueller, A. M. S., Kenkel, J., Ahn, G.-O., Dutt, S., … Strober, S. (2015). Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clinical Cancer Research , 21(16), 3727–39.
- A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency
  Dvorak, C. C., Horn, B. N., Puck, J. M., Czechowicz, A., Shizuru, J. A., Ko, R. M., & Cowan, M. J. (2014). A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency. PEDIATRIC TRANSPLANTATION, 18(6), 602–8.
- Genetic susceptibility loci for lethal graft-versus-host disease in MHC-identical mice: Initial results from a genome-wide scan.
  Cao, T. M., Pang, W. W., Grumet, R. C., Lazzeroni, L. C., & Shizuru, J. A. (2004). Genetic susceptibility loci for lethal graft-versus-host disease in MHC-identical mice: Initial results from a genome-wide scan. BLOOD, 104(11), 328B–328B.
- Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning
  Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. BONE MARROW TRANSPLANTATION, 50(10), 1286–92.
- Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy.
  Chhabra, A., Ring, A. M., Weiskopf, K., Schnorr, P. J., Gordon, S., Le, A. C., … Shizuru, J. A. (2016). Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Science Translational Medicine, 8(351), 351ra105-?
- Brief report: Tolerance and chimerism after renal and hematopoietic-cell transplantation
  Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Millan, M. T., Shizuru, J. A., … Strober, S. (2008). Brief report: Tolerance and chimerism after renal and hematopoietic-cell transplantation. NEW ENGLAND JOURNAL OF MEDICINE, 358(4), 362–68.
- B6.g7 mice reconstituted with BDC2 center dot 5 non-obese diabetic (BDC2 center dot 5NOD) stem cells do not develop autoimmune diabetes
  Rajasekaran, N., Wang, N., Hang, Y., Macaubas, C., Rinderknecht, C., Beilhack, G. F., … Mellins, E. D. (2013). B6.g7 mice reconstituted with BDC2 center dot 5 non-obese diabetic (BDC2 center dot 5NOD) stem cells do not develop autoimmune diabetes. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 174(1), 27–37.
- Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation
  Mueller, A. M. S., Linderman, J. A., Florek, M., Miklos, D., & Shizuru, J. A. (2010). Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 107(33), 14721–26.
- Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment.
  Müller, A. M. S., Poyser, J., Küpper, N. J., Burnett, C., Ko, R. M., Kohrt, H. E. K., … Shizuru, J. A. (2014). Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment. Blood, 123(18), 2882–92.
- INFLAMMATORY DESTRUCTION OF PANCREATIC BETA-CELLS IN GAMMA-INTERFERON TRANSGENIC MICE
  Sarvetnick, N., Shizuru, J., Liggitt, D., & Stewart, T. (1989). INFLAMMATORY DESTRUCTION OF PANCREATIC BETA-CELLS IN GAMMA-INTERFERON TRANSGENIC MICE. Presented at the 3RD SYMP ON IMMUNOLOGICAL RECOGNITION, COLD SPRING HARBOR,NY,NY: COLD SPRING HARBOR LABORATORY PRESS.
- Blood Stem Cell Activity Is Arrested by Th1-Mediated Injury Preventing Engraftment following Nonmyeloablative Conditioning.
  Müller, A. M. S., Florek, M., Kohrt, H. E. K., Küpper, N. J., Filatenkov, A., Linderman, J. A., … Shizuru, J. A. (2016). Blood Stem Cell Activity Is Arrested by Th1-Mediated Injury Preventing Engraftment following Nonmyeloablative Conditioning. Journal of Immunology , 197(10), 4151–62.
- Foxp3(+) regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis
  Pierini, A., Nishikii, H., Baker, J., Kimura, T., Kwon, H.-S., Pan, Y., … Negrin, R. S. (2017). Foxp3(+) regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis. NATURE COMMUNICATIONS, 8.
- Decoupling the Functional Pleiotropy of Stem Cell Factor by Tuning c-Kit Signaling
  Ho, C. C. M., Chhabra, A., Starkl, P., Schnorr, P.-J., Wilmes, S., Moraga, I., … Garcia, K. C. (2017). Decoupling the Functional Pleiotropy of Stem Cell Factor by Tuning c-Kit Signaling. CELL, 168(6), 1041-?
- An innovative biologic system for photon-powered myocardium in the ischemic heart.
  Cohen, J. E., Goldstone, A. B., Paulsen, M. J., Shudo, Y., Steele, A. N., Edwards, B. B., … Woo, Y. J. (2017). An innovative biologic system for photon-powered myocardium in the ischemic heart. Science Advances, 3(6), e1603078.
- HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.
  Spinner, M. A., Fernández-Viña, M., Creary, L. E., Quinn, O., Elder, L., Arai, S., … Rezvani, A. R. (2017). HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Advances, 1(17), 1347–57.
- Macrochimerism and clinical transplant tolerance.
  Scandling, J. D., Busque, S., Lowsky, R., Shizuru, J., Shori, A., Engleman, E., … Strober, S. (2018). Macrochimerism and clinical transplant tolerance. Human Immunology.
- Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation
  Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., … Lowsky, R. (2018). Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation. BLOOD ADVANCES, 2(6), 681–90.
- SDF 1-alpha Attenuates Myocardial Injury Without Altering the Direct Contribution of Circulating Cells.
  Goldstone, A. B., Burnett, C. E., Cohen, J. E., Paulsen, M. J., Eskandari, A., Edwards, B. E., … Woo, Y. J. (2018). SDF 1-alpha Attenuates Myocardial Injury Without Altering the Direct Contribution of Circulating Cells. Journal of Cardiovascular Translational Research.
- Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
  Sockolosky, J. T., Trotta, E., Parisi, G., Picton, L., Su, L. L., Le, A. C., … Garcia, K. C. (2018). Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. SCIENCE, 359(6379), 1037-+.
- Anti-Human CD117 Antibodies Mediate Clearance of Myelodysplastic Syndrome Hematopoietic Stem Cells and Facilitate Establishment of Normal Hematopoiesis in Transplantation
  Pang, W. W., Czechowicz, A., Poyser, J., Park, C. Y., Weissman, I. L., & Shizuru, J. A. (2018). Anti-Human CD117 Antibodies Mediate Clearance of Myelodysplastic Syndrome Hematopoietic Stem Cells and Facilitate Establishment of Normal Hematopoiesis in Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.
- Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation
  Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., … Johnston, L. (2017). Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(10), 1744–48.
- Selective HSC-Ablation Using CD117 Antibody-Drug-Conjugates Enables Safe and Effective Murine and Human Hematopoietic Stem Cell Transplantation
  Czechowicz, A., Palchaudhuri, R., Scheck, A., Hu, Y., Hoggatt, J., Saez, B., … Rossi, D. J. (2018). Selective HSC-Ablation Using CD117 Antibody-Drug-Conjugates Enables Safe and Effective Murine and Human Hematopoietic Stem Cell Transplantation. MOLECULAR THERAPY. CELL PRESS.
- Relationship Between Mixed Chimerism and Acceptance of HLA-matched and -Mismatched Kidney Transplants after Withdrawal of Immunosuppressive Drugs
  Busque, S., Scandling, J., Lowsky, R., Shizuru, J., Jensen, K., Shori, A., … Strober, S. (2018). Relationship Between Mixed Chimerism and Acceptance of HLA-matched and -Mismatched Kidney Transplants after Withdrawal of Immunosuppressive Drugs. TRANSPLANTATION. LIPPINCOTT WILLIAMS & WILKINS.
- Long term follow-up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
  Maffini, E., Storer, B. E., Sandmaier, B. M., Bruno, B., Sahebi, F., Shizuru, J. A., … Storb, R. (2018). Long term follow-up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica.
- Anti-human CD117 antibody-mediated bone marrow niche clearance in non-human primates and humanized NSG mice.
  Kwon, H.-S., Logan, A. C., Chhabra, A., Pang, W. W., Czechowicz, A., Tate, K., … Shizuru, J. A. (2019). Anti-human CD117 antibody-mediated bone marrow niche clearance in non-human primates and humanized NSG mice. Blood.
- Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation.
  Czechowicz, A., Palchaudhuri, R., Scheck, A., Hu, Y., Hoggatt, J., Saez, B., … Rossi, D. J. (2019). Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. Nature Communications, 10(1), 617.
- Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice.
  Pang, W. W., Czechowicz, A., Logan, A. C., Bhardwaj, R., Poyser, J., Park, C. Y., … Shizuru, J. A. (2019). Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. Blood.
- Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort
  Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., … Lowsky, R. (2018). Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort. BLOOD. AMER SOC HEMATOLOGY.
- Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma
  Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., … Miklos, D. B. (2018). Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.
  Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., … Negrin, R. S. (2019). Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight, 4(10).
- Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice
  Pang, W. W., Czechowicz, A., Logan, A. C., Bhardwaj, R., Poyser, J., Park, C. Y., … Shizuru, J. A. (2019). Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. BLOOD, 133(19), 2069–78.
- Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice
  Kwon, H.-S., Logan, A. C., Chhabra, A., Pang, W. W., Czechowicz, A., Tate, K., … Shizuru, J. A. (2019). Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice. BLOOD, 133(19), 2104–8.
- Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients
  Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., … Negrin, R. S. (2019). Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI INSIGHT, 4(10).
- Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance.
  George, B. M., Kao, K. S., Kwon, H.-S., Velasco, B. J., Poyser, J., Chen, A., … Weissman, I. L. (2019). Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance. Cell Stem Cell.
- Modeling chronic Graft-vs-Host disease in MHC-matched mouse strains: genetics, graft composition and tissue targets.
  Müller, A. M., Min, D., Wernig, G., Levy, R. B., Perez, V. L., Herretes, S., … Shizuru, J. A. (2019). Modeling chronic Graft-vs-Host disease in MHC-matched mouse strains: genetics, graft composition and tissue targets. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.
- Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.
  Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S., Johnston, L. J., … Lowsky, R. (2019). Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Advances, 3(16), 2454–64.
- Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.
  Shadman, M., Maloney, D. G., Storer, B., Sandmaier, B. M., Chauncey, T. R., Smedegaard Andersen, N., … Sorror, M. L. (2019). Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. Bone Marrow Transplantation.
- Conditioning Perspectives for Primary Immunodeficiency Stem Cell Transplants.
  Shaw, P., Shizuru, J., Hoenig, M., & Veys, P. (2019). Conditioning Perspectives for Primary Immunodeficiency Stem Cell Transplants. Frontiers in Pediatrics, 7, 434.
- Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal.
  Busque, S., Scandling, J. D., Lowsky, R., Shizuru, J., Jensen, K., Waters, J., … Strober, S. (2020). Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal. Science Translational Medicine, 12(528).
- Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era
  Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., … Cunanan, K. (2020). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.
- Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
  Cooper, J. P., Storer, B. E., Granot, N., Gyurkocza, B., Sorror, M. L., Chauncey, T. R., … Sandmaier, B. M. (2020). Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. Haematologica.
- Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.
  Lemieux, C., Muffly, L. S., Rezvani, A., Lowsky, R., Iberri, D. J., Craig, J. K., … Sidana, S. (2020). Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation.
- Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.
  Weng, W.-K. K., Arai, S., Rezvani, A., Johnston, L., Lowsky, R., Miklos, D., … Kim, Y. H. (2020). Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Advances, 4(18), 4474–82.
- Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.
  Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., … Sidana, S. (2020). Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.
- Jun Activation in Dermal Fibroblasts Promotes Fibrosis and Inflammation in Sclerodermatous Graft-vs-host Disease in Mice and Humans
  Mueller, A., Cui, L., Lerbs, T., King, M., Muscat, C., Shibata, T., … Wernig, G. (2020). Jun Activation in Dermal Fibroblasts Promotes Fibrosis and Inflammation in Sclerodermatous Graft-vs-host Disease in Mice and Humans. BONE MARROW TRANSPLANTATION. SPRINGERNATURE.
- Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.
  Lemieux, C., Muffly, L. S., Iberri, D. J., Rezvani, A., Lowsky, R., Frank, M. J., … Sidana, S. (2020). Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).
  Tam, E. L., Iberri, D. J., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M. J., … Sidana, S. (2020). Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
  Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., … Sidana, S. (2021). Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy.
- Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.
  Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., … Sidana, S. (2021). Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era. Transplantation and Cellular Therapy.
- Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.
  Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., … Sidana, S. (2021). Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation.
- Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report
  Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., … Arai, S. (2021). Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report. BONE MARROW TRANSPLANTATION. SPRINGERNATURE.
- CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
  Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., … Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine.
- Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
  Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., … Miklos, D. B. (2021). Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Advances, 5(16), 3147–3151.
- Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients.
  Jensen, K. P., Hongo, D., Ji, X., Zheng, P., Pawar, R. D., Wu, H.-H., … Strober, S. (2021). Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients. Blood Advances.
- 5-Azacytidine depletes hematopoietic stem cells and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice.
  Bankova, A. K., Pang, W., Velasco, B. J., Long-Boyle, J. R., & Shizuru, J. A. (2021). 5-Azacytidine depletes hematopoietic stem cells and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice. Blood Advances.
- Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.
  Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., … Sidana, S. (2021). Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy. Blood Advances.
- Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.
  Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., … Miklos, D. B. (2021). Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
  Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., … Sidana, S. (2021). Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. BLOOD ADVANCES, 5(21), 4465–4475.
- Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.
  Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., … Arai, S. (1800). Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report. Transplantation and Cellular Therapy.
- Exploring Potential Innate Immune Targets to Treat Fibrosis and Chronic Inflammation in Chronic Graft-Versus-Host Disease
  Paulson, N., De Souza, C., Cui, L., Lerbs, T., Poyser, J., Kooshesh, M., … Wernig, G. (2022). Exploring Potential Innate Immune Targets to Treat Fibrosis and Chronic Inflammation in Chronic Graft-Versus-Host Disease. MODERN PATHOLOGY. SPRINGERNATURE.
- Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.
  Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., … Muffly, L. (2022). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy.
- Mgta-145+Plerixafor Provides GCSFFree Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study
  Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S., Tamaresis, J., Le, A., … Miklos, D. B. (2021). Mgta-145+Plerixafor Provides GCSFFree Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study. BLOOD. AMER SOC HEMATOLOGY.
- JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naive Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID)
  Agarwa, R., Dvorak, C. C., Prockop, S., Kwon, H.-S., Long-Boyle, J. R., Le, A., … Shizuru, J. A. (2021). JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naive Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID). BLOOD. AMER SOC HEMATOLOGY.
- Selective Targeting of Immune Modulatory Proteins to Mitigate Fibrosis and Inflammation in Sclerodermatous Graft-Vs-Host Disease
  Cui, L., De Souza, C., Lerbs, T., Poyser, J., Kooshesh, M., Saleem, A., … Wernig, G. (2021). Selective Targeting of Immune Modulatory Proteins to Mitigate Fibrosis and Inflammation in Sclerodermatous Graft-Vs-Host Disease. BLOOD. AMER SOC HEMATOLOGY.
- Anti-CD117 CAR T Cells Incorporating a Safety Switch Eradicate Acute Myeloid Leukemia and Deplete Human Hematopoietic Stem Cells
  Magnani, C. F., Myburgh, R., Russkamp, N. F., Pascolo, S., Shizuru, J. A., Neri, D., & Manz, M. G. (2021). Anti-CD117 CAR T Cells Incorporating a Safety Switch Eradicate Acute Myeloid Leukemia and Deplete Human Hematopoietic Stem Cells. BLOOD. AMER SOC HEMATOLOGY.
- Curative islet and hematopoietic cell transplantation in diabetic mice without toxic bone marrow conditioning.
  Chang, C. A., Bhagchandani, P., Poyser, J., Velasco, B. J., Zhao, W., Kwon, H.-S., … Kim, S. K. (2022). Curative islet and hematopoietic cell transplantation in diabetic mice without toxic bone marrow conditioning. Cell Reports, 41(6), 111615.
- Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
  Spinner, M. A., Sica, R. A., Tamaresis, J. S., Lu, Y., Chang, C., Lowsky, R., … Arai, S. (2023). Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood.
- Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
  Philip, S., Lowsky, R., Johnston, L. J., Arai, S., Meyer, E. H., Negrin, R. S., … Agrawal, V. (2022). Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era. BLOOD. AMER SOC HEMATOLOGY.
- Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease
  Chin, M., Shizuru, J. A., Muffly, L., Shiraz, P., Johnston, L. J., Lowsky, R., … Arai, S. (2022). Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease. BLOOD. AMER SOC HEMATOLOGY.
- Multi-Omics Profiling of Skin Biopsies of Patients with Sclerodermatous Graft-Vs-Host Disease Suggests Therapeutic Potential of Targeting Don't Eat Me Signals
  Cui, L., De Souza, C., Lerbs, T., Poyser, J., Yu, C., Rieger, K., … Wernig, G. (2022). Multi-Omics Profiling of Skin Biopsies of Patients with Sclerodermatous Graft-Vs-Host Disease Suggests Therapeutic Potential of Targeting Don't Eat Me Signals. BLOOD. AMER SOC HEMATOLOGY.
- Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma
  Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamaresis, J., Patil, S., Hanson, P. J., … Dahiya, S. (2022). Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes
  Philip, S., Srinagesh, H. K., Hamilton, M. P., Gentille, C., Mina, A., Arai, S., … Frank, M. J. (2022). The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes. BLOOD. AMER SOC HEMATOLOGY.
- Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
  Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M. S., Good, Z., … Alizadeh, A. A. (2022). Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects. BLOOD. AMER SOC HEMATOLOGY.
- Multi-Omics Profiling of Skin Biopsies of Patients with Sclerodermatous Graft-vs-Host Disease Suggests Therapeutic Potential of Targeting Don't Eat Me Signals
  Wadsworth, P., De Souza, C., Cui, L., Yiu, C., Poyser, J., Rieger, K., … Wernig, G. (2023). Multi-Omics Profiling of Skin Biopsies of Patients with Sclerodermatous Graft-vs-Host Disease Suggests Therapeutic Potential of Targeting Don't Eat Me Signals. LABORATORY INVESTIGATION. ELSEVIER SCIENCE INC.
- Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells.
  Magnani, C. F., Myburgh, R., Brunn, S., Chambovey, M., Ponzo, M., Volta, L., … Manz, M. G. (2023). Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells. Molecular Therapy Oncolytics, 30, 56–71.
- Safety-Switch Engineered Anti-CD117 CAR T Cells Eradicate Human Acute Myeloid Leukemia and Hematopoietic Stem Cells
  Magnani, C. F., Myburgh, R., Brunn, S., Chambovey, M., Ponzo, M., Volta, L., … Manz, M. G. (2023). Safety-Switch Engineered Anti-CD117 CAR T Cells Eradicate Human Acute Myeloid Leukemia and Hematopoietic Stem Cells. MOLECULAR THERAPY. CELL PRESS.
- Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD.
  Bader, C. S., Pavlova, A., Lowsky, R., Muffly, L., Shiraz, P., Arai, S., … Meyer, E. (2023). Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD. Blood Advances.
- GVHD ASSESSMENT IN PHASE 1 STUDY OF BRIQUILIMAB (JSP191), LOW DOSE IRRADIATION AND FLUDARABINE CONDITIONING IN OLDER ADULTS WITH MDS/AML UNDERGOING ALLOGENEIC HCT
  Youn, M., Muffly, L., Artz, A., Lee, C., Gandhi, A., Varma, A., … Pang, W. (2023). GVHD ASSESSMENT IN PHASE 1 STUDY OF BRIQUILIMAB (JSP191), LOW DOSE IRRADIATION AND FLUDARABINE CONDITIONING IN OLDER ADULTS WITH MDS/AML UNDERGOING ALLOGENEIC HCT. BONE MARROW TRANSPLANTATION. SPRINGERNATURE.
- CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias
  Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., … Alizadeh, A. A. (2023). CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias. BLOOD. AMER SOC HEMATOLOGY.
- Radiation and Busulfan-Free Hematopoietic Stem Cell Transplantation Using Briquilimab (JSP191) Anti-CD117 Antibody-Conditioning, Transient Immunosuppression and TCR a ß + T-Cell/CD19+B-Cell Depleted Haploidentical Grafts in Patients with Fanconi Anemia
  Agarwal, R., Bertaina, A., Soco, C. F., Saini, G., Kunte, N., Hiroshima, L., … Czechowicz, A. (2023). Radiation and Busulfan-Free Hematopoietic Stem Cell Transplantation Using Briquilimab (JSP191) Anti-CD117 Antibody-Conditioning, Transient Immunosuppression and TCR a ß + T-Cell/CD19+B-Cell Depleted Haploidentical Grafts in Patients with Fanconi Anemia. BLOOD. AMER SOC HEMATOLOGY.
- Final Results from Phase 1 Study of Briquilimab, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myeloid Leukemia in Complete Remission and Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation
  Gandhi, A., Artz, A., Lee, C. J., Varma, A., Scott, B. L., Kwon, H.-S., … Muffly, L. S. (2023). Final Results from Phase 1 Study of Briquilimab, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myeloid Leukemia in Complete Remission and Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation. BLOOD. AMER SOC HEMATOLOGY.
- Targeting of CD25+Activated T Cells in Gvhd-Associated Marrow Suppression and Cytopenias
  John, T. D., Valine, L., Barbarito, G., Kwon, H.-S., Arai, S., Martin-Kool, B., … Weinberg, K. I. (2023). Targeting of CD25+Activated T Cells in Gvhd-Associated Marrow Suppression and Cytopenias. BLOOD. AMER SOC HEMATOLOGY.
- Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus
  Villar-Prados, A., Meyer, E. H., Sutherland, K., Negrin, R. S., Arai, S., Frank, M. J., … McClellan, S. (2023). Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus. BLOOD. AMER SOC HEMATOLOGY.
- CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.
  Hamilton, M. P., Craig, E., Gentille Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., … Miklos, D. B. (2024). CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Advances.
- Management of post-autologous transplant relapse in patients with T-cell lymphomas.
  Veilleux, O., Socola, F., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., … Weng, W.-K. K. (2024). Management of post-autologous transplant relapse in patients with T-cell lymphomas. American Journal of Hematology.

View More Publications

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease

Axicabtagene Ciloleucel Expanded Access Study

Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant

Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease

Haploid Allogeneic Transplant Using the CliniMACS System

TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors

Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation

High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma

Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)

Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus

Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)

Targeted Therapy of Bronchiolitis Obliterans Syndrome

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

Double Cord Versus Haploidentical (BMT CTN 1101)

Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)

Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma

Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients

90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL

Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)

Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation

Specializing In

Practice Locations

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA

Palo Alto, CA

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive

900 Blake Wilbur Dr, Fl 2

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Ratings

(9 Ratings)

Overall Rating

4.9/5

View Ratings by Category

5.0/5

Friendliness

5.0/5

Explanations

5.0/5

Listens

5.0/5

Care provider's efforts to include you in decisions about your care

4.6/5

Recommended to others

0.0/5

Wait times

How Our Ratings Work

The Patients Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

Patient Satisfaction Survey Disclaimer

Patient Reviews

(77 reviews)

I love my dr and her staff

Jan 2025

•

Verified SHC Patient

Excellent care ! Very pleased with the level of care and response if there is any questions.

Nov 2024

•

Verified SHC Patient

Great Doctor!!!

Oct 2024

•

Verified SHC Patient

She is an excellent physician, a great listener.

Oct 2024

•

Verified SHC Patient

Dr Silverman is the best!

Aug 2024

•

Verified SHC Patient

Extremely pleased she is doing video visits with a patient, given her demanding schedule, after eight years!

Jul 2024

•

Verified SHC Patient

She is a very excellent Doctor for me. She asks questions and wants you to ask questions and she will always follow-up. Thank you, Doctor Shizuru.

May 2024

•

Verified SHC Patient

She is a very good doctor

Apr 2024

•

Verified SHC Patient

wonderful experience

Feb 2024

•

Verified SHC Patient

Dr. Shizuru has been an excellent doctor for the medical and physical procedures plus the great care she has provided for me. Iâ€™m am so grateful for her being there to make sure I get the best treatment and very intuitive for the whatever I need to give me the quality of care I need .

Feb 2024

•

Verified SHC Patient

I love her I trust her with my health she is awesome

Feb 2024

•

Verified SHC Patient

Love her!

Jan 2024

•

Verified SHC Patient

She is very knowledgeable. she explains everything so that I understand whatâ€™s going on.

Jan 2024

•

Verified SHC Patient

Very nice

Nov 2023

•

Verified SHC Patient

She is an amazing doctor, very knowledgeable and professional and kind.

Nov 2023

•

Verified SHC Patient

I find her so knowledgeable, and kind. I feel in very good hands.

Oct 2023

•

Verified SHC Patient

She is very thorough and I understood everything she had to say.

Aug 2023

•

Verified SHC Patient

Iâ€™m the beneficiary of excellent professional service and personal care. Past, present, and future patients have been, are, and will be very fortunate indeed to receive such care.

Jul 2023

•

Verified SHC Patient

Dr Shizuru was wonderful during this whole process and I would ask for her again in the future if needed.

Jun 2023

•

Verified SHC Patient

Great doctor, thank you for your help Dr. Shizuru

Jun 2023

•

Verified SHC Patient

Sheâ€™s the greatest!

Apr 2023

•

Verified SHC Patient

wonderful clinician who is greatly appreciated

Feb 2023

•

Verified SHC Patient

Dr. Shizuru is a great doctor, I feel blessed to been treated about my cancer with her

Dec 2022

•

Verified SHC Patient

I am very pleased with both Stanford and Dr. Shizuru.

Dec 2022

•

Verified SHC Patient

Best Dr ever1â ¤

Oct 2022

•

Verified SHC Patient

They answered any and all questions I had

Aug 2022

•

Verified SHC Patient

She is a great doctor, saved my life, my gratitude forever, thank you doctor Shizuru

Aug 2022

•

Verified SHC Patient

Always appreciate Dr. Shizuruâ€™s time, patience and expertise!

Jul 2022

•

Verified SHC Patient

Highest regard for her excellent professional and interpersonal skills

Jul 2022

•

Verified SHC Patient

I appreciate Dr. Shizuru as an expert in the field, she is kind, professional, and friendly

Jun 2022

•

Verified SHC Patient

Stanford is the best one, is an honor been there, my condition is an unusual type of cancer, they have a lot of expertise! Blessings to Stanford

May 2022

•

Verified SHC Patient

Sheâ€™s excellent

May 2022

•

Verified SHC Patient

Dr. Shizuru is an GREAT practitioner and I would recommend her to anyone. She feels like family.

Apr 2022

•

Verified SHC Patient

She's great

Mar 2022

•

Verified SHC Patient

What a great doctor! Really been impressed with her knowledge, listening skills and compassion. Blessed to have her and my healthcare team!

Mar 2022

•

Verified SHC Patient

Dr. Shizuru is an excellent researcher and we need excellent practitioners to perform this task. Human beings are multidimensional and practitioners must see them in a holistic way not just as a specialty all our systems are connected and everything affects us be it on the emotional, physical mental, family members around you are all part of the healing process and they must be included in the care plan as well as listening to what the patient knows about themselves that an outsider can never know because we are not that individual especially when one is dealing with a life-threatening situation, your family really matters. They are your support system and they should not be ignored.

Mar 2022

•

Verified SHC Patient

Incredible physician and researcher. Highly recommend her!

Feb 2022

•

Verified SHC Patient

She's excellent

Feb 2022

•

Verified SHC Patient

I love Dr. Shizuru! She is thorough, helpful and coordinates great with my Kaiser team.

Feb 2022

•

Verified SHC Patient

She was extremely helpful and wonderful we were very blessed to have her as my Doctor thankyou

Jan 2022

•

Verified SHC Patient

I have always felt comfortable with and confident in Dr. Shizuru's decisions regarding my health care. I enjoy my appointments with her.

Jan 2022

•

Verified SHC Patient

Dr Shizuru is a knowledgeable and helpful Doctor. I respect her explanation of my care

Jan 2022

•

Verified SHC Patient

Great doctor! I'm very happy with the care I've received from her, Marqui and the Stanford bmt team.

Dec 2021

•

Verified SHC Patient

Very knowledgeable and professional

Dec 2021

•

Verified SHC Patient

The top Doctors and team in the UNITED STATES.

Nov 2021

•

Verified SHC Patient

Dr. Shizuru rocks. She and the staff are excellent health care providers. Dr. Shizuru asks questions, listens and provides thorough information. I am grateful to have been matched up with her for my stem cell transplant.

Nov 2021

•

Verified SHC Patient

She is excellent

Oct 2021

•

Verified SHC Patient

Dr. Shizuru is the Best!

Sep 2021

•

Verified SHC Patient

Dr Shizuru is an excellent physician. She is experienced, friendly, easy to talk to as well as a good listener. I have been extremely pleased being one of her patients.

Sep 2021

•

Verified SHC Patient

She is excellent

Aug 2021

•

Verified SHC Patient

Doctor is very professional. A very attentive listener. Very thoughtful. Very kind.

Aug 2021

•

Verified SHC Patient

I've been very pleased to have her as my bmt doctor.

Aug 2021

•

Verified SHC Patient

Excellent doctor and very easy to talk too.

Aug 2021

•

Verified SHC Patient

Outstanding in both my video and office visits in person!

Jul 2021

•

Verified SHC Patient

Dr. Shizuru is the best! Always look forward to talking with her. Wish she could be my doctor permanently.

May 2021

•

Verified SHC Patient

I have experienced the care of Dr Shizuru and highly respect her opinion. I have been very happy with he care I received at Stanford.

Apr 2021

•

Verified SHC Patient

Thank you!

Jul 2018

•

Verified SHC Patient

Dr. Shizuru is awesome!!

Mar 2018

•

Verified SHC Patient

All the providers are very nice and I would recommend with other people.

Dec 2017

•

Verified SHC Patient

The greatest.

Nov 2017

•

Verified SHC Patient

Outstanding communications listening ability the best!

Jun 2017

•

Verified SHC Patient

Dr. Shizuru is a pre eminent physician. I feel very fortunate to be a patient under her care and treatment. After facing numerous difficulties and challenges after my bone marrow transplant, she was crucial to my survival and progress to date.

Jan 2017

•

Verified SHC Patient

The Health Care Provider is someone I think is trustworthy and reliable.

Jan 2017

•

Verified SHC Patient

Dr. Shizuru listened and answered every question.

Oct 2016

•

Verified SHC Patient

Excellent in everything.

Sep 2016

•

Verified SHC Patient

Both the staff & facility were outstanding.

Feb 2016

•

Verified SHC Patient

I've been coming to the BMT clinic for 23 years... always a dedicated, concerned and communicative group. My comments are for my full history not only the last visit.

Dec 2015

•

Verified SHC Patient

Answered above & beyond all my questions, especially being an off-island patient. Very hospitable.

Nov 2015

•

Verified SHC Patient

Great confidence in care provider & staff.

Aug 2015

•

Verified SHC Patient

Fantastic doctor and very personable.

Jul 2015

•

Verified SHC Patient

Dr. Shizuru is our hero!!!

Jun 2015

•

Verified SHC Patient

Dr's. & nurses are great - they are over-worked & need more support staff.

Dec 2014

•

Verified SHC Patient

Dr. Shizuru has been wonderful through my whole treatment. Always answers our many questions.

Nov 2014

•

Verified SHC Patient

Dr. Shizuru is a fabulous doctor - in ever way possible. She is committed, caring, compassionate and extremely intelligent. I hope Stanford realizes how fortunate they really are to have her on their list of great doctors!

Nov 2014

•

Verified SHC Patient

Dr. Shizuru and her staff are great!

Oct 2014

•

Verified SHC Patient

Kaiser/Stanford provided excellent care which saved my life.

Sep 2014

•

Verified SHC Patient

Every time I go everyone knows my name and are all so very nice.

May 2014

•

Verified SHC Patient

View More Patient Reviews

Referring Physicians

PHYSICIAN HELPLINE

Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.

Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

LOG INTO MEDLINK

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

Judith Shizuru

Blood and marrow transplant specialist, Hematologist, Hematologist-Oncologist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(77 reviews)

Referring Physicians

PHYSICIAN HELPLINE

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Judith Shizuru

Blood and marrow transplant specialist, Hematologist, Hematologist-Oncologist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(77 reviews)

Referring Physicians

PHYSICIAN HELPLINE